Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK-Inhibitor Vecabrutinib at Analyst & Investor Event dur...
November 28 2018 - 7:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced it will
provide a program update for vecabrutinib, the Company’s oral,
reversible, non-covalent, BTK inhibitor which is currently being
evaluated in an ongoing Phase 1b/2 clinical trial in adults with
relapsed chronic lymphocytic leukemia (CLL) and other B-cell
malignancies. The program will include data presented in the poster
titled “Preliminary Safety, Pharmacokinetic, and Pharmacodynamic
Results from a Phase 1b/2 Dose Escalation and Cohort-Expansion
Study of the Noncovalent, Reversible Bruton’s Tyrosine Kinase
Inhibitor (BTKi), Vecabrutinib, in B-Lymphoid Malignancies,”
(Abstract No: 3141). This update will take place at a dinner event
hosted by Sunesis during the 60th American Society of Hematology
(ASH) Annual Meeting and Exposition on Sunday, December 2, 2018, at
8:00 p.m. PT.
Sunesis’ executive management team will present
an update on vecabrutinib from the ongoing Phase 1b/2
dose-escalation study evaluating the safety, pharmacokinetics,
pharmacodynamics, and antitumor activity of vecabrutinib in
B-lymphoid malignancy patients with prior BTK therapy. The
Phase 1b/2 trial is an open-label, sequential-group study that is
enrolling patients across eight leading sites in the United
States.
The event will also feature a discussion with a
key opinion leader in CLL, William G. Wierda, M.D., Ph.D.,
Department of Leukemia, Division of Cancer Medicine, The University
of Texas MD Anderson Cancer Center. Dr. Wierda is one of the
principal investigators of Sunesis’ ongoing vecabrutinib trial.
The event on December 2 will begin at 8:00 p.m.
PT and is intended for institutional investors and sell-side
analysts only. Please contact maeve@argopartners.com for more
information. A live webcast of the event, with slides, will be
available on the Investors section of the Sunesis website at
www.sunesis.com beginning at approximately 8:30 p.m. PT, and will
be subsequently archived for 90 days.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing new therapeutics for the treatment of hematologic and
solid cancers. Sunesis has built an experienced drug development
organization committed to improving the lives of people with
cancer. The Company is focused on advancing its novel kinase
inhibitor pipeline, with an emphasis on its oral non-covalent BTK
inhibitor vecabrutinib. Vecabrutinib is currently being evaluated
in a Phase 1b/2 study in adults with chronic lymphocytic leukemia
and other B-cell malignancies that have progressed after prior
therapies. The Company’s proprietary PDK1 inhibitor SNS-510 is in
preclinical development. PDK1 is a master kinase that activates
other kinases important to cell growth and survival including
members of the AKT, PKC, RSK, and SGK families. Sunesis plans to
submit an IND for SNS-510 in 2019. Sunesis is exploring strategic
alternatives for vosaroxin, a late-stage investigational product
for relapsed or refractory AML. Sunesis also has an interest in the
pan-RAF inhibitor TAK-580 which is licensed to Takeda. TAK-580 is
in a clinical trial for pediatric low-grade glioma.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis
Pharmaceuticals, Inc.
This press release contains forward-looking
statements, including statements related to the continued
development of vecabrutinib (SNS-062), the timing of the Phase 1b/2
trial of vecabrutinib and the therapeutic potential of
vecabrutinib, further development and potential of its kinase
inhibitor pipeline, and planned development of SNS-510 and TAK-580.
Words such as “expect,” “look forward,” “will” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Sunesis' current
expectations. Forward-looking statements involve risks and
uncertainties. Sunesis' actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the risk related
to the timing or conduct of Sunesis' clinical trials, including the
vecabrutinib Phase 1b/2 trial, the risk that Sunesis' clinical or
preclinical studies for vecabrutinib, SNS-510 or other product
candidate may not demonstrate safety or efficacy or lead to
regulatory approval, the risk that data to date and trends may not
be predictive of future data or results, risks related to the
timing or conduct of Sunesis' clinical trials, that Sunesis'
development activities for vecabrutinib or SNS-510 could be
otherwise halted or significantly delayed for various reasons, that
Sunesis may not be able to receive regulatory approval of
vecabrutinib, or SNS-510 in the U.S. or Europe, and risks related
to Sunesis' ability to raise the capital that it believes to be
accessible and is required to fully finance the development and
commercialization of vecabrutinib, SNS-510 and other product
candidates. These and other risk factors are discussed under "Risk
Factors" and elsewhere in Sunesis' Quarterly Report on Form 10-Q
for the quarter ended September 30, 2018 and Sunesis' other filings
with the Securities and Exchange Commission. Sunesis
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein reflect any change in Sunesis' expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based.
Investor
and Media Inquiries: |
Maeve Conneighton |
|
|
Willie Quinn |
Argot Partners |
|
|
Sunesis Pharmaceuticals
Inc. |
212-600-1902 |
|
|
650-266-3716 |
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2023 to Sep 2024